The Company's Annual Report on Form 10-K will be available from the U.S. Securities and Exchange Commission's website at http://www.sec.gov or the "Investor Information" section of the Company's Web site at http://www.vermillion.com.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements
This news release contains forward-looking statements that involve
significant risks and uncertainties, including statements regarding
Vermillion's plans, objectives, expectations and intentions and the risks
and uncertainties discussed in Vermillion's latest Form 10-K and
Vermillion's periodic reports on Form 10-Q and Form 8-K. These
forward-looking statements are based on Vermillion's current expectations.
Vermillion is providing this information as of the date of this news
release and does not undertake any obligation to update any forward-looking
statements as a result of new information, future events or otherwise.
Forward-looking statements cannot be guaranteed and actual results may
differ materially from Vermillion's current expectations. You are
encouraged to read Vermillion's reports filed with the U.S. Securities an
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved